Overview

Aminocamptothecin in Treating Patients With T-cell Lymphoma

Status:
Completed
Trial end date:
2000-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients with advanced cutaneous T-cell lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Yale University
Collaborator:
National Cancer Institute (NCI)
Treatments:
Lenograstim